High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia.

ABSTRACT: Background:Acute myeloid leukemia (AML) pertains to a hematologic malignancy with heterogeneous therapeutic responses. Improvements in risk stratification in AML patients are warranted. MicroRNAs have been associated with the pathogenesis of AML. Methods:To examine the prognostic value of miR-25, 162 cases with de novo AML were classified into two groups according to different treatment regimens. Results:In the chemotherapy group, cases with upregulated miR-25 expression showed relatively longer overall survival (OS; P?=?0.0086) and event-free survival (EFS; P?=?0.019). Multivariable analyses revealed that miR-25 upregulation is an independent predictor for extended OS (HR?=?0.556, P?=?0.015) and EFS (HR?=?0.598, P?=?0.03). In addition, allogeneic hematopoietic stem cell transplantation (allo-HSCT) circumvented the poor prognosis that was related to miR-25 downregulation with chemotherapy. The expression level pattern of miR-25 coincided with AML differentiation and proliferation, which included HOXA and HOXB cluster members, as well as the HOX cofactor MEIS1. The MYH9 gene was identified as a direct target of miR-25. Conclusions:The miR-25 levels are correlated with prognosis in AML independently of other powerful molecular markers. The expression of miR-25 may contribute to the selection of the optimal treatment regimen between chemotherapy and allo-HCST for AML patients.

SUBMITTER: Niu M 

PROVIDER: S-EPMC6505210 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature